Aldagen, Inc.

Duke University

University of South Florida

Saneron Ccel Therapeutics, Inc.

Stemco Biomedical, Inc.

Andrew E Balber

Tracy Gentry

Sandra J Foster

Paul R Sanberg

Alison Elizabeth Willing

Svitlana Garbuzova-Davis

Joanne Kurtzberg

Cyndy Davis-Sanberg

Arjun Saha

Paula Scotland

Nicole Kuzmin-Nichols

Pamela Noldner

The present disclosure provides compositions and methods for treating demyelinating conditions. More particularly, the present disclosure relates to compositions including DUOC-01 cell product and an anti-inflammatory agent; methods for preparing such compositions; and methods of using such compositions in combination or in conjunction with each other for treatment of treating demyelinating conditions.

Compositions and methods for the treatment of demyelinating conditions

The present invention relates to populations of stem cells, methods for isolating these stem cell populations, and methods repairing, regenerating, and reconstituting tissues using the these stem cell populations. The invention additionally relates to methods of screening agents that promote growth, engraftment, or differentiation of stem cells.

Stem cell populations and methods of use

A method of treating a patient with a neurodegenerative disease, such as ALS, using progenitor cells isolated from human umbilical cord blood. Non-invasive transplantation of aldehyde dehydrogenase (ALDH) expressing progenitor cells provides cell replacement and protection of motor neurons.

Treating amyotrophic lateral sclerosis (ALS)with isolated aldehyde dehydrogenase-positive umbilical cord blood cells

Populations of stem cells and methods for their isolation and use are provided. These stem cell populations comprise aldehyde dehydrogenase positive (ALDH) cells isolated from bone marrow, and ALDHCD105cells derived from any stem cell source. These populations may also comprise cells expressing such surface markers as CD34, CD38, CD41, CD45, CD105, CD133, CD135, CD117, and HLA-DR, and/or are substantially free from such cell surface markers as CD3, CD7, CD 10, CD 13, CD 14, C1319, CD33, CD35, CD56, CD 127, CD 138, and glycophorin A. The population may also comprise cells expressing CD90. The stem cell populations of the invention are isolated from a stem cell source such as bone marrow, peripheral blood, umbilical cord blood, and fetal liver. Methods of the invention comprise isolating and purifying stem cell populations from stem cell sources, and methods of using these cells to reconstitute, repair, and regenerate tissues.

Growing community of inventors

Durham, NC, United States of America

Andrew E Balber